Couple of marginally relevant articles
|
4
|
Resverlogix Corp.
|
May 26, 2022 01:52AM
|
Re: Ethics Approval?
|
4
|
Resverlogix Corp.
|
Oct 19, 2021 05:04PM
|
Re: In Brief Published: 14 May 2021 CARDIOVASCULAR RISK Apabetalone in chronic kidney disease
|
4
|
Resverlogix Corp.
|
May 21, 2021 02:01AM
|
Re: Finance
|
4
|
Resverlogix Corp.
|
Apr 13, 2021 11:44PM
|
Re: In Brief Published: 14 May 2021 CARDIOVASCULAR RISK Apabetalone in chronic kidney disease
|
4
|
Resverlogix Corp.
|
May 21, 2021 02:08AM
|
Re: Health Canada Issues Resverlogix Authorization to Begin Immediate Clinical Studies of Apabetalone for COVID-19
|
4
|
Resverlogix Corp.
|
Apr 12, 2021 12:37PM
|
Reposting with Link Included
|
4
|
Resverlogix Corp.
|
Jun 22, 2021 06:36PM
|
BET inhibition and epilepsy
|
4
|
Resverlogix Corp.
|
Jun 08, 2021 02:08AM
|
Re: The FDA's highly arbitrary decisions
|
4
|
Resverlogix Corp.
|
Jun 08, 2021 02:19AM
|
Re: Health Canada Issues Resverlogix Authorization to Begin Immediate Clinical Studies of Apabetalone for COVID-19
|
4
|
Resverlogix Corp.
|
Apr 12, 2021 05:15PM
|
Re: Health Canada Issues Resverlogix Authorization to Begin Immediate Clinical Studies of Apabetalone for COVID-19
|
4
|
Resverlogix Corp.
|
Apr 12, 2021 05:27PM
|
Re: Zenith Epigenetics did not respond to invitatations in this one
|
4
|
Zenith Epigenetics
|
May 31, 2021 12:03PM
|
Questions for AGM attenders
|
4
|
Resverlogix Corp.
|
Oct 30, 2019 12:48AM
|
Re: Presentation
|
4
|
Resverlogix Corp.
|
May 13, 2021 05:44PM
|
Re: BD-selectivity vs. BET protein selectivity
|
4
|
Resverlogix Corp.
|
Oct 06, 2018 05:09AM
|
Re heart & covid. May be repeat but note Nichols comment
|
4
|
Resverlogix Corp.
|
Feb 27, 2021 11:41PM
|
Fabry competition
|
4
|
Resverlogix Corp.
|
Feb 27, 2021 11:45PM
|
Re: Fabry competition
|
4
|
Resverlogix Corp.
|
Feb 27, 2021 11:51PM
|
Posted before but PMC version, RVX & Sepsis
|
4
|
Resverlogix Corp.
|
Apr 01, 2021 05:47PM
|
Alz Forum article from April
|
3
|
Resverlogix Corp.
|
May 17, 2021 02:40AM
|